Glucose Metabolism Disorders  >>  CCX140  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CCX140 / Amgen, CSL Behring
NCT01028963 / 2009-016051-22: A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus

Checkmark POC data in diabetic nephropathy
May 2013 - May 2013: POC data in diabetic nephropathy
Checkmark Data
Jul 2011 - Jul 2011: Data
Checkmark Data
More
Completed
2
159
Europe, RoW
Placebo, pioglitazone, CCX140-B
ChemoCentryx
Type 2 Diabetes Mellitus
10/10
11/10
NCT01440257 / 2011-003049-16: A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria

Completed
2
20
Europe
Placebo, CCX140-B
ChemoCentryx
Diabetic Nephropathy, Type 2 Diabetes Mellitus
02/13
09/13
NCT01447147 / 2011-001267-49: A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy

Checkmark Initial presentation from 52-week trial for diabetic nephropathy
Apr 2015 - Jun 2015: Initial presentation from 52-week trial for diabetic nephropathy
Checkmark From 52-week trial for diabetic nephropathy
Dec 2014 - Dec 2014: From 52-week trial for diabetic nephropathy
Completed
2
332
Europe, RoW
Placebo, CCX140-B
ChemoCentryx
Diabetic Nephropathy, Type 2 Diabetes Mellitus
08/14
12/14

Download Options